These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 36641771)

  • 1. Thyroid autoimmunity following alemtuzumab treatment in multiple sclerosis patients: a prospective study.
    Kazakou P; Tzanetakos D; Vakrakou AG; Tzartos JS; Evangelopoulos ΜE; Anagnostouli M; Stathopoulos P; Kassi GN; Stefanis L; Kilidireas C; Zapanti E
    Clin Exp Med; 2023 Oct; 23(6):2885-2894. PubMed ID: 36641771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alemtuzumab-Induced Thyroid Dysfunction Exhibits Distinctive Clinical and Immunological Features.
    Pariani N; Willis M; Muller I; Healy S; Nasser T; McGowan A; Lyons G; Jones J; Chatterjee K; Dayan C; Robertson N; Coles A; Moran C
    J Clin Endocrinol Metab; 2018 Aug; 103(8):3010-3018. PubMed ID: 29878256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alemtuzumab-induced autoimmune thyroid events in patients with relapsing-remitting multiple sclerosis: A real-life and monocentric experience at a tertiary-level centre.
    Manso J; Zhu YH; Margoni M; Rinaldi F; Censi S; Carducci S; Cosma C; Plebani M; Gallo P; Mian C
    Clin Endocrinol (Oxf); 2022 Sep; 97(3):331-338. PubMed ID: 34724236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Prospective Study to Evaluate the Possible Role of Cholecalciferol Supplementation on Autoimmunity in Hashimoto's Thyroiditis.
    Bhakat B; Pal J; Das S; Charaborty SK; SircarMedical NR; Kolkata ; RGKar ; NorthBengal ; Siliguri
    J Assoc Physicians India; 2023 Jan; 71(1):1. PubMed ID: 37116030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alemtuzumab-induced thyroid events in multiple sclerosis: a systematic review and meta-analysis.
    Scappaticcio L; Castellana M; Virili C; Bellastella G; Centanni M; Cannavò S; Campennì A; Ruggeri RM; Giovanella L; Trimboli P
    J Endocrinol Invest; 2020 Feb; 43(2):219-229. PubMed ID: 31452116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alemtuzumab induces severe orbitopathy in relapsing-remitting multiple sclerosis.
    Rodríguez de Vera Gómez P; Méndez Muros M; Torres Cuadro A; Toyos Sáenz de Miera FJ; López Ruiz R; Guerrero Vázquez R; García González JJ; Garrido Hermosilla AM; Martín Hernández T
    J Neurol; 2024 Jan; 271(1):486-496. PubMed ID: 37773417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of autoimmune antibodies to predict secondary autoimmunity in patients with relapsing-remitting multiple sclerosis treated with alemtuzumab: A nationwide prospective survey.
    Sandgren S; Novakova L; Axelsson M; Amirbeagi F; Kockum I; Olsson T; Malmestrom C; Lycke J
    Front Neurol; 2023; 14():1137665. PubMed ID: 37006489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence, Risk Factors, and Clinical and Biochemical Characteristics of Alemtuzumab-Induced Graves Disease.
    Ueland GÅ; Ueland HO; Stokland AM; Bhan A; Schønberg A; Sollid ST; Morgas DE; Holmøy T; Lima K; Methlie P; Løvås K; Torkildsen Ø; Husebye ES
    J Clin Endocrinol Metab; 2024 Jan; 109(2):344-350. PubMed ID: 37708353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Longitudinal Characterization of Autoantibodies to the Thyrotropin Receptor (TRAb) During Alemtuzumab Therapy: Evidence that TRAb May Precede Thyroid Dysfunction by Many Years.
    Muller I; Willis M; Healy S; Nasser T; Loveless S; Butterworth S; Zhang L; Draman MS; Taylor PN; Robertson N; Dayan CM; Ludgate ME
    Thyroid; 2018 Dec; 28(12):1682-1693. PubMed ID: 30351224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of Autoimmune Thyroid Disease in Multiple Sclerosis Patients Post-Alemtuzumab Improves Treatment Response.
    Sovetkina A; Nadir R; Scalfari A; Tona F; Murphy K; Rigoni E; Dorsey R; Malik O; Nandoskar A; Singh-Curry V; Nicholas R; Martin N
    J Clin Endocrinol Metab; 2020 Sep; 105(9):. PubMed ID: 32667988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Graves' disease induced by Alemtuzumab in relapsing-remitting multiple sclerosis patients: an observational study in a reference center.
    Rodríguez de Vera Gómez P; García-González JJ; Ravé-García R; López Ruiz R; Torres-Cuadro A; Eichau-Madueño S; García-García C; Martín-Hernández T
    J Endocrinol Invest; 2022 Oct; 45(10):1977-1990. PubMed ID: 35718853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Graves' disease with spontaneous resolution following ocrelizumab in primary progressive multiple sclerosis.
    Duarte DB; Silva AMD; Freitas C; Cardoso H
    Endocr Regul; 2021 Sep; 55(3):169-173. PubMed ID: 34523298
    [No Abstract]   [Full Text] [Related]  

  • 13. Alemtuzumab-related thyroid dysfunction in a phase 2 trial of patients with relapsing-remitting multiple sclerosis.
    Daniels GH; Vladic A; Brinar V; Zavalishin I; Valente W; Oyuela P; Palmer J; Margolin DH; Hollenstein J
    J Clin Endocrinol Metab; 2014 Jan; 99(1):80-9. PubMed ID: 24170099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of secondary autoimmune diseases with alemtuzumab treatment for multiple sclerosis: a systematic review and meta-analysis.
    Yang J; Sun Y; Zhou X; Zhang D; Xu Z; Cao J; Fan B
    Front Immunol; 2024; 15():1343971. PubMed ID: 38690271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autoimmune thyroid disease following treatment with alemtuzumab for multiple sclerosis.
    Alamo A; Condorelli RA; La Vignera S; Calogero AE
    Int J Immunopathol Pharmacol; 2019; 33():2058738419843690. PubMed ID: 30968726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Alemtuzumab-induced Graves' disease].
    Sheremeta MS; Korchagina MO; Guseinova RM; Schmidt TE; Nizhegorodova KS; Sviridenko NY; Melnichenko GA
    Probl Endokrinol (Mosk); 2023 Jun; 69(3):51-57. PubMed ID: 37448247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Graves' disease after treatment with alemtuzumab for multiple sclerosis.
    Tsourdi E; Gruber M; Rauner M; Blankenburg J; Ziemssen T; Hofbauer LC
    Hormones (Athens); 2015; 14(1):148-53. PubMed ID: 25402383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alemtuzumab-induced thyroid disease: A Danish cohort study.
    Hansen JF; Magyari M; Rasmussen ÅK; Sellebjerg F; Feldt-Rasmussen U
    Mult Scler Relat Disord; 2024 Nov; 91():105880. PubMed ID: 39293122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autoimmune thyroid disease in the use of alemtuzumab for multiple sclerosis: a review.
    Aranha AA; Amer S; Reda ES; Broadley SA; Davoren PM
    Endocr Pract; 2013; 19(5):821-8. PubMed ID: 23757618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autoimmune Thyroid Diseases in Patients Treated with Alemtuzumab for Multiple Sclerosis: An Example of Selective Anti-TSH-Receptor Immune Response.
    Rotondi M; Molteni M; Leporati P; Capelli V; Marinò M; Chiovato L
    Front Endocrinol (Lausanne); 2017; 8():254. PubMed ID: 29033895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.